Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,192 INR
Change Today -18.60 / -0.58%
Volume 5.3K
GLXO On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:05 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline pharmaceutic (GLXO) Snapshot

Open
3,220
Previous Close
3,211
Day High
3,230
Day Low
3,181
52 Week High
01/27/15 - 3,550
52 Week Low
06/26/14 - 2,352
Market Cap
270.4B
Average Volume 10 Days
9.9K
EPS TTM
56.87
Shares Outstanding
84.7M
EX-Date
07/23/15
P/E TM
56.1x
Dividend
62.50
Dividend Yield
1.57%
Current Stock Chart for GLAXOSMITHKLINE PHARMACEUTIC (GLXO)

Related News

No related news articles were found.

glaxosmithkline pharmaceutic (GLXO) Related Businessweek News

No Related Businessweek News Found

glaxosmithkline pharmaceutic (GLXO) Details

GlaxoSmithKline Pharmaceuticals Limited operates as research-based healthcare and pharmaceutical company worldwide. It manufactures, distributes, and trades prescription medicines for a range of therapeutic areas, including analgesic, anti-infective, anti-inflammatory, anti-parasitic, cardiovascular, dermatology, diabetes, endocrine, gastrointestinal, gynaecology, immunosupressants, nutritional, respiratory, CNS, and oncology diseases. The company also offers vaccines for the prevention of various diseases comprising hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia, and others. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is based in Mumbai, India.

Founded in 1924

glaxosmithkline pharmaceutic (GLXO) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: 26.1M
Executive Director of Technical and Executive...
Total Annual Compensation: 7.0M
Executive Director of Human Resources and Exe...
Total Annual Compensation: 7.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline pharmaceutic (GLXO) Key Developments

GlaxoSmithKline Pharmaceuticals Ltd Announces Executive Appointments

GlaxoSmithKline Pharmaceuticals Ltd. announced that Mr. Simon Harford, Non-Executive Director will retire from service on May 18, 2015 and will cease to be a Director of the company from May 18, 2015. The Board of Directors at its meeting held on May 18, 2015 has appointed Mr. Regis Simard as the Non-Executive Director of the company from May 18, 2015.

Glaxosmithkline Pharmaceuticals Limited Recommends Dividend for the Fifteen Month Period Ended March 31, 2015, Payable on or After August 1, 2015

GlaxoSmithKline Pharmaceuticals Ltd. announced that the Board of Directors of the company at its meeting held on May 18, 2015, recommended a dividend of INR 62.50 per equity share for the fifteen month period ended March 31, 2015. The dividend if approved by the shareholders will be paid on or after August 01, 2015.

GlaxoSmithkline Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended March 31, 2015 and Audited Consolidated and Standalone Earnings Results for the Fifteen Months Ended March 31, 2015

GlaxoSmithkline Pharmaceuticals Limited reported unaudited standalone earnings results for the first quarter ended March 31, 2015 and audited consolidated and standalone earnings results for the fifteen months ended March 31, 2015. For the quarter, the company's net sales were INR 6,134.7 million against INR 5,998.5 million a year ago. Profit from operations before other income and exceptional items were INR 1,210.2 million against INR 1,033.5 million a year ago. Profit from ordinary activities before tax was INR 1,556.9 million against INR 1,482.3 million a year ago. Net profit from ordinary activities was INR 1,028.5 million or INR 12.1 per basic and diluted share against INR 965.4 million or INR 11.4 per basic and diluted share a year ago. For the fifteen months, on standalone basis, the company's net sales were INR 32,534.1 million against INR 25,201.7 million for the twelve months period ended December 31, 2013. Profit from operations before other income and exceptional items were INR 6,018.4 million against INR 5,022.0 million for the twelve months period ended December 31, 2013. Profit from ordinary activities before tax was INR 7,486.3 million against INR 7,293.2 million for the twelve months period ended December 31, 2013. Net profit from ordinary activities was INR 4,716.5 million or INR 55.7 per basic and diluted share against INR 5,018.8 million or INR 59.3 per basic and diluted share for the twelve months period ended December 31, 2013. For the fifteen months, on consolidated basis, the company's net sales were INR 32,724.7 million against INR 25,383.3 million for the twelve months period ended December 31, 2013. Profit from operations before other income and exceptional items were INR 6,076.3 million against INR 5,083.5 million for the twelve months period ended December 31, 2013. Profit from ordinary activities before tax was INR 7,556.8 million against INR 7,114.5 million for the twelve months period ended December 31, 2013. Net profit from ordinary activities was INR 4,764.1 million or INR 56.2 per basic and diluted share against INR 4,816.7 million or INR 56.9 per basic and diluted share for the twelve months period ended December 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLXO:IN 3,192.15 INR -18.60

GLXO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLXO.
View Industry Companies
 

Industry Analysis

GLXO

Industry Average

Valuation GLXO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PHARMACEUTIC, please visit www.gsk-india.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.